WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 23, 2017--
OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that it will host a conference call
at 4:30 p.m. ET on Thursday, March 2, 2017 to discuss fourth quarter and
fiscal year 2016 financial results and provide a general corporate
The live call can be accessed by dialing +1-888-424-8151 for U.S.
callers and +1-847-585-4422 for international callers five minutes prior
to the start of the call and by providing the passcode 7862456. A live
webcast of the conference call will be available online from the
Investors section of the Company’s website at www.ovascience.com.
A replay of the conference call will be available from 7:00 p.m. ET on
Thursday, March 2, 2017 through 11:59 p.m. ET on Thursday, March 9,
2017, and may be accessed by visiting OvaScience’s website or by dialing
+1-888-843-7419 for U.S. callers and +1-630-652-3042 for international
callers. The replay access code is 7862456#.
OvaScience, Inc. (NASDAQ: OVAS) is a global
fertility company dedicated to improving treatment options for women
around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because it believes women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining.
OvaScience is developing OvaTureSM, a potential
next-generation in vitro fertilization (IVF) treatment that could help a
woman produce healthy, young, fertilizable eggs without hormone
injections and OvaPrimeSM, which could increase a woman’s egg
reserve. OvaScience’s AUGMENTSM treatment, a fertility option
designed to improve IVF success rates, is available in certain IVF
clinics in select international regions. OvaScience treatments are not
available in the U.S. For more information, visit www.ovascience.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170223006346/en/
Source: OvaScience, Inc.
Media and Investor Contact: